ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1428

Ankylosing Spondylitis Related Mortality Trends in USA from 1999-2020: Analysis of CDC Wonder Database
Abstract Number: 1331

Anti-beta-2-glycoprotein-1 IgA antibodies facilitate macrophage cholesterol loading and influence coronary atherosclerosis progression in a dose-dependent manner in rheumatoid arthritis
Abstract Number: 0647

Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus: an open-label pilot study
Abstract Number: 0812

Anti-CD206 CAR T Cell Immunotherapy Mitigates Dermal Pathology in Systemic Sclerosis
Abstract Number: 1559

Anti-Cytolethal Distending Toxin Antibodies in Systemic Sclerosis: Associations with Gastrointestinal Disease and Immune Dysregulation
Abstract Number: 2417

Anti-dense fine speckled 70 antibodies in undefined disease, systemic autoimmune rheumatic diseases and controls
Abstract Number: 0281

Anti-IL-6 Autoantibodies and IL-6 Signalling in Idiopathic Inflammatory Myopathies
Abstract Number: 2652

Anti-mitochondrial antibodies in systemic sclerosis target enteric neurons and are associated with GI dysmotility
Abstract Number: 0529

Anti-PeptidylArginine Deiminase-2 (anti-PAD2) Autoantibodies in Psoriatic Arthritis
Abstract Number: 1219

Anti-Ro52 Antibody Identifies Patients with More Severe Lung disease among Patients with Idiopathic Inflammatory Myopathy
Abstract Number: 2386

Anti-Trim72 Auto-antibodies In Systemic Lupus Erythematosus Patients and a Lupus Mouse Model with Myocarditis Compromise Membrane Repair in Mouse & Human Cardiomyocytes
Abstract Number: 1512

Anti-U1-RNP Antibody Positivity is Associated with Elevated Interferon Score in SLE Irrespective of Disease Activity: A Transcriptome Analysis in Japanese Patients
Abstract Number: 1607

Antibiotic Prophylaxis during Treatment of ANCA-associated Vasculitis with Rituximab: Data from a Multicenter Cohort
Abstract Number: 0076

Antibodies to malondialdehyde-acetaldehyde are associated with circulating inflammatory mediators during the preclinical stages of rheumatoid arthritis
Abstract Number: 0631

Antibodies to Type I and Type III Interferons at Diagnosis Predispose to Serious Infections on Follow Up in an Inception cohort of SLE (INSPIRE) from India.

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].